Advanced Delivery Systems and Novel Psilocin Derivatives for Enhanced Therapeutic Applications.

Psychedelic compounds like psilocybin and psilocin show therapeutic promise for neurological and psychiatric disorders, but their clinical use is limited by poor bioavailability, rapid metabolism, and stability issues. This Patent Highlight reviews recent innovations in drug delivery systems and psilocin analogs, including controlled-release systems, ester analogs, and acetal/ketal derivatives. These patents present novel approaches to improving stability, bioavailability, and efficacy, potentially leading to more effective treatments for depression, chronic pain, and neurodegenerative diseases.

Study at a glance

Abstract

Psychedelic compounds, particularly psilocybin and psilocin, have shown significant therapeutic potential in treating neurological and psychiatric disorders. However, their bioavailability, rapid metabolism, and stability challenges have limited their clinical use. This Patent Highlight reviews recent innovations in psychedelic drug delivery systems and the development of psilocin analogs aimed at improving their pharmacokinetic and pharmacodynamic profiles. Three patents-focused on controlled-release delivery systems, ester analogs, and acetal/ketal derivatives-present novel approaches to enhancing the stability, bioavailability, and efficacy of psilocin and related compounds. These advancements promise more effective treatments for conditions such as depression, chronic pain, and neurodegenerative diseases.